MedTrace Logo

Investigation of Vascular Inflammation in Migraine Using Molecular Nano-imaging and Black Blood Imaging MRI

NCT02549898 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2022-07-27

No results posted yet for this study

Summary

The investigators aim to investigate inflammation of cranial and meningeal arteries during pharmacologically induced migraine attacks, using ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles and black blood imaging (BBI) MRI.

Conditions

  • Migraine Headache
  • Migraine Without Aura

Interventions

DRUG

Feraheme

Feraheme is an USPIO agent, which will be applied as a contrast agent to visualize vascular inflammation in unilateral migraine without aura.

DRUG

Cilostazol

Cilostazol will be applied to provoke migraine attacks in migraineurs

OTHER

USPIO-MRI

USPIO-MRI scans will be performed in order to assess possible vascular inflammation associated with migraine attacks.

OTHER

BBI-MRI

Black blood MRI scans will be performed in order to asses changes in vessel wall thickness due to possible vascular inflammation associated with migraine attacks.

Sponsors & Collaborators

  • Danish Headache Center

    lead OTHER

Principal Investigators

  • Sabrina Khan, MD · Danish Headache Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2018-06-30
Completion
2018-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02549898 on ClinicalTrials.gov